Quantcast

Latest Timolol Stories

2008-09-15 12:00:35

Othera Pharmaceuticals, Inc., today announced that it has initiated dosing in a Phase I/II clinical trial to determine the safety and efficacy of topical OT-730 in patients with ocular hypertension and glaucoma. The study is a randomized, multi-center, investigator-masked, timolol- and placebo-controlled evaluation of the safety and efficacy of OT-730 in reducing the intraocular pressure in subjects with ocular hypertension or open-angle glaucoma. Subjects will be randomized to one of 0.75%...

2008-08-28 12:01:22

Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that the Company filed a complaint in the U.S. District Court for the District of Columbia against the U.S. Food and Drug Administration (FDA) requesting a declaratory judgment related to Hi-Tech's Abbreviated New Drug Application (ANDA) for dorzolamide and timolol ophthalmic solution, the generic for Merck's Cosopt(R). Hi-Tech seeks confirmation that it is entitled to a 180-day period of market exclusivity as the first applicant to submit...

2008-08-01 06:00:46

Othera Pharmaceuticals has submitted an investigational new drug application to the FDA for OT-730, an oculoselective beta-blocker, as a potential treatment for glaucoma. A Phase I-II safety and efficacy trial is planned for completion by the end of 2008. This study is a randomized, multi-center, investigator-masked, timolol- and placebo-controlled, Phase I-II evaluation of the safety and efficacy of OT-730 ophthalmic solution in reducing the intraocular pressure in subjects with ocular...

2008-07-30 09:01:27

Othera Pharmaceuticals, Inc., announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for OT-730, an oculoselective beta-blocker, as a potential treatment for glaucoma. A Phase 1-2 safety and efficacy trial is planned for completion by the end of 2008. OT-730 is a novel, internally developed next generation topical beta-blocker designed to lower intra-ocular pressure (IOP), the leading risk factor for developing...

2008-07-03 09:01:19

FDC has received approval from the FDA for its abbreviated new drug application, Ciprofloxacin ophthalmic solution. FDC's Ciprofloxacin Ophthalmic Solution is a broad spectrum antibiotic used for occular surface infections. The company has recently received approval for Timolol maleate ophthalmic solution. Another abbreviated new drug application Ofloxacin ophthalmic solution is in the final stages of approval.


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.